MapLight Therapeutics, Inc. (MPLT)
MPLT moved a median of -0.41% 30 minutes after news, and -1.28% by the close. How MPLT actually reacts to news — the realized, point-in-time move the market made, measured across 204 labeled events over the last three years with zero look-ahead.
MPLT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 202 |
| 30-min | -0.41% | 44% | 202 |
| 60-min | +0.30% | 53% | 202 |
| to close | -1.28% | 44% | 200 |
| Middle 50% of MPLT reactions | -1.43% to +2.12% |
|---|---|
| Median reaction (30-min) | -0.41% |
| Measured reactions | 204 |
Half of all MapLight Therapeutics, Inc. news events land between -1.43% and +2.12% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MPLT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | -0.17% | 46% | -0.85% |
| Coverage initiations | 36 | -0.47% | 47% | +0.21% |
| Rating reiterations | 19 | +0.54% | 58% | +1.78% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how MPLT ranks against every other measured name →
That’s how MPLT usually reacts — get an email when it moves on news →Email me when MPLT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MPLT's baseline. Nothing else.
Recent MPLT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics | Press release | GlobeNewswire | -1.51% | +4.87% | |
| Form EFFECT MapLight Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -1.65% | +1.51% | |
| Form S-1/A MapLight Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | -1.49% | -1.45% | |
| Form S-1 MapLight Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | -1.04% | +2.19% | |
| MapLight Therapeutics to Participate in Upcoming Investor Conference | Press release | GlobeNewswire | +0.21% | -1.72% | |
| Form 10-Q MapLight Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.58% | -2.41% | |
| Form 8-K MapLight Therapeutics, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -0.58% | -2.41% | |
| MapLight Therapeutics Announces $150 Million Private Placement Financing | Press release | GlobeNewswire | +1.68% | -2.85% | |
| MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.58% | -2.41% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages MapLight Therapeutics, Inc. (MPLT) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.16% | — | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating MapLight Therapeutics, Inc. (MPLT) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +11.34% | — | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MapLight Therapeutics, Inc. (MPLT) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.73% | -0.98% | |
| MapLight Therapeutics, Inc. (MPLT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.49% | -3.15% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages MapLight Therapeutics, Inc. (MPLT) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.20% | -1.26% | |
| MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law | Press release | PR Newswire | +1.48% | -2.33% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against MapLight Therapeutics, Inc. (MPLT) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.60% | -2.54% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages MapLight Therapeutics, Inc. (MPLT) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.07% | +0.04% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MapLight Therapeutics, Inc. (MPLT) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.18% | +13.20% | |
| Form 8-K MapLight Therapeutics, For: Jul 27 | SEC filing · Form 8-K | SEC EDGAR | -9.09% | -23.69% | |
| MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia | Press release | GlobeNewswire | -9.09% | -23.69% | |
| MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law | Press release | Business Wire | +2.02% | -16.84% | |
| Form 8-K MapLight Therapeutics, For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | +1.82% | +7.13% | |
| MapLight Therapeutics Announces Changes to Board of Directors | Press release | GlobeNewswire | +1.82% | +7.13% | |
| Form 8-K MapLight Therapeutics, For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +7.52% | +6.47% | |
| MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder | Press release | GlobeNewswire | +7.52% | +6.47% | |
| Form 8-K MapLight Therapeutics, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +7.52% | +6.47% | |
| Form 10-Q MapLight Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +0.95% | |
| Form 8-K MapLight Therapeutics, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.95% | |
| MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | +0.95% | |
| MapLight Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.19% | -6.23% | |
| MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results | Press release | GlobeNewswire | +0.06% | -2.10% | |
| Form 8-K MapLight Therapeutics, For: Apr 23 | SEC filing · Form 8-K | SEC EDGAR | -0.91% | +5.29% | |
| Form ARS MapLight Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.91% | +5.29% | |
| Form DEF 14A MapLight Therapeutics, For: Jun 23 | SEC filing · Form DEF | SEC EDGAR | -0.91% | +5.29% | |
| Form DEFA14A MapLight Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.91% | +5.29% | |
| Form 10-K MapLight Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +9.14% | |
| Form 8-K MapLight Therapeutics, For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +9.14% | |
| Form S-8 MapLight Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +9.14% | |
| MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | +9.14% | |
| MapLight Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +4.23% | +1.91% | |
| Form 8-K MapLight Therapeutics, For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | -0.34% | +2.97% | |
| MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 | Press release | GlobeNewswire | -0.34% | +2.97% | |
| MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis | Press release | GlobeNewswire | -0.06% | +0.64% | |
| SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies | Press release | GlobeNewswire | +0.00% | -3.96% | |
| Form 10-Q MapLight Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.24% | +11.42% | |
| Form 8-K MapLight Therapeutics, For: Dec 04 | SEC filing · Form 8-K | SEC EDGAR | +0.24% | +11.42% | |
| MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress | Press release | GlobeNewswire | +0.24% | +11.42% | |
| Form 8-K MapLight Therapeutics, For: Oct 26 | SEC filing · Form 8-K | SEC EDGAR | +0.36% | -1.31% | |
| MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | +0.36% | -1.31% | |
| Form S-8 MapLight Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.05% | -3.47% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MPLT section they belong to.
Where else MPLT is measured.
MPLT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is MapLight Therapeutics, Inc.'s median reaction calculated?
Every labeled MPLT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 204 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of MPLT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MPLT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.